NasdaqGS:ANABBiotechs
AnaptysBio (ANAB) Q4 Profit Of US$49.6 Million Tests Longstanding Loss-Making Narrative
AnaptysBio's FY 2025 Headline Numbers
AnaptysBio (ANAB) has put up a sharp swing in its latest quarter, with Q4 FY 2025 revenue at US$108.2 million and basic EPS of US$1.79, compared with a loss in the same quarter a year earlier and a trailing twelve month basic EPS of US$0.46 loss on revenue of US$234.6 million. Over recent periods, the company has seen quarterly revenue move from US$43.1 million in Q4 2024 to US$22.3 million in Q2 2025 and US$76.3 million in Q3 2025 before reaching...